FIGURE 3 from B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors

Generation and characterization of allogeneic B7H3.CAR EBVSTs. A, Fold expansion of EBVSTs following mock (UT) or B7H3.CAR transduction. B, CAR expression at final harvest. C, Percentages of EBVSTs expressing TNFα and IFNγ after overnight stimulation of cells with media, HIV or EBV pepmixes. D, UT and B7H3.CAR EBVST cytolysis of various B7-H3+ tumor cell lines after 24 hours of coculture at a 1:1 E:T ratio. E, Serial cytolysis of NCI-H1299 NSCLC cells by B7H3.CAR EBVSTs over five rounds of cocultures at a 1:2 E:T ratio. F, Cell surface staining of CD25 on EBVSTs after treatment with varying concentrations of plate-bound (coated) or soluble B7-H3 in 2-Ig or 4-Ig forms. G, Cytotoxicity of B7H3.CAR EBVST against NCI-N87 or NCI-H1299 cells at the indicated timepoints in the presence of varying concentrations of soluble 2-Ig or 4-Ig B7-H3. Data presented are from 6 (A and B), 3 (C, D, F, and G), or 2 (E) healthy donors and represent means ± SD where applicable.